Tularik Announces the Formation of German Subsidiary.Business Editors and Health/Medical Writers BIOWIRE2K SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--April 16, 2001 Tularik Inc. (Nasdaq:TLRK) today announced the formation of Tularik GmbH, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. located in Regensburg, Germany. The subsidiary will develop new assays and implement high-throughput screening High-throughput screening (HTS), is a method for scientific experimentation especially used in drug discovery and relevant to the fields of biology and chemistry. Purpose and method for the identification of small molecule drugs that act to regulate gene expression. "Although the pharmaceutical industry is multinational, relatively few U.S. biotech companies have so far taken advantage of the enormous opportunities and resources in Europe," said Ulrike Schindler, Ph.D., managing director of Tularik GmbH. Over the last two years, biotech in Europe has blossomed, with interest and activity especially strong in Germany. "We intend to take advantage of this European opportunity," said Dr. Schindler, "to recruit excellent scientists, to identify the most promising European-developed technologies and to apply these to Tularik's broad-based drug discovery efforts." Dr. Schindler, a German native, joined Tularik eight years ago after completing a Ph.D. in biochemistry at Albert-Ludwig University in Freiburg, Germany and the University of Pennsylvania (body, education) University of Pennsylvania - The home of ENIAC and Machiavelli. http://upenn.edu/. Address: Philadelphia, PA, USA. . "As one of Tularik's first scientists, Ulrike is steeped in the company's drug discovery and development philosophy; as a native of Germany she is also well acquainted with the latest scientific and corporate developments in European biotech. Thus, she is ideally suited to build and run our first European base of operations Noun 1. base of operations - installation from which a military force initiates operations; "the attack wiped out our forward bases" base air base, air station - a base for military aircraft army base - a large base of operations for an army ," said Terry Rosen, Ph.D., executive vice president of Operations at Tularik. Dr. Schindler is an expert in the application of gene regulation technology to drug discovery. She is a past program director of Tularik's drug discovery effort in Immune Disorders. Her scientific staff in Germany includes two other German natives, Dr. Holger Beckmann and Dr. Ralf Schwandner, both of whom worked at Tularik's headquarters in South San Francisco before relocating to Regensburg. A 2,000-year-old Bavarian city on the banks of the Danube, Regensburg has become a hotbed hotbed, low, glass-covered frame structure for starting tender plants. It differs from a cold frame only in that the soil is heated—either artificially as by underground electric wiring or steampipes, or naturally with partially fermented stable manure, which of German biotechnology and other high-technology business activity in recent years. Located about 120 kilometers northeast of Munich -- site of the renowned Max Planck Noun 1. Max Planck - German physicist whose explanation of blackbody radiation in the context of quantized energy emissions initiated quantum theory (1858-1947) Max Karl Ernst Ludwig Planck, Planck Institute for Biochemistry -- Regensburg is home to subsidiaries of many multinational corporations
in full Bayerische Motoren Werke AG German automaker. Founded as an aircraft engine manufacturer in 1916, the company assumed the name Bayerische Motoren Werke and became known for its high-speed motorcycles in the 1920s. and Siemens. Tularik's German operations are located within BioPark Regensburg, an innovative biotechnology business incubator developed in part by the Free State of Bavaria, the German national government and the city of Regensburg. "Tularik is very impressed with the commitment that has been made by this city and the German government in support of the biotech industry," said Dr. Schindler. "There is good cooperation between local universities, the state government and the private sector. "The BioPark incubator that we're now a part of is the product of that cooperative spirit. It enables us to take advantage of excellent infrastructure, which is essential for biotechnology R&D, as well as proximity to the University of Regensburg The University of Regensburg, situated in Regensburg, in Bavaria, Germany, was founded on July 18 1962 by the Bavarian parliament. Bavaria's fourth university saw its first lectures during the 1967-68 winter semester , initially housing a faculty of Law and Business Sciences as and its associated clinic, where we have access to medical libraries and other specialized facilities. "The atmosphere for doing research and development is quite stimulating. Being at the heart of biotech in this part of Germany, we're able to interact readily with our counterparts across the industry. We're also close to Munich, and have been able to recruit from that city some very fine technical and laboratory staff." Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs that act through the regulation of gene expression Gene modulation redirects here. For information on therapeutic regulation of gene expression, see therapeutic gene modulation.
. . Tularik programs address cancer, viral diseases, inflammation, immune disorders, lipid disorders, diabetes, bacterial diseases and obesity. Tularik has established strategic partnerships with Japan Tobacco Inc., Roche Bioscience and Knoll AG. For more information, visit Tularik's Internet website at www.tularik.com. This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes", "anticipates", "plans", "expects", "will", "intend" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Tularik to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in Tularik's SEC reports, including its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion